Bionano Genomics Inc
NASDAQ:BNGO
Intrinsic Value
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. [ Read More ]
The intrinsic value of one BNGO stock under the Base Case scenario is 4.58 USD. Compared to the current market price of 0.75 USD, Bionano Genomics Inc is Undervalued by 84%.
Valuation Backtest
Bionano Genomics Inc
Run backtest to discover the historical profit from buying and selling BNGO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bionano Genomics Inc
Current Assets | 140.1m |
Cash & Short-Term Investments | 66.8m |
Receivables | 9.7m |
Other Current Assets | 63.7m |
Non-Current Assets | 74.3m |
PP&E | 32.5m |
Intangibles | 34m |
Other Non-Current Assets | 7.8m |
Current Liabilities | 100m |
Accounts Payable | 10.4m |
Accrued Liabilities | 9.1m |
Other Current Liabilities | 80.5m |
Non-Current Liabilities | 18.2m |
Long-Term Debt | 3.6m |
Other Non-Current Liabilities | 14.6m |
Earnings Waterfall
Bionano Genomics Inc
Revenue
|
36.1m
USD
|
Cost of Revenue
|
-26.6m
USD
|
Gross Profit
|
9.6m
USD
|
Operating Expenses
|
-147.5m
USD
|
Operating Income
|
-138m
USD
|
Other Expenses
|
-94.5m
USD
|
Net Income
|
-232.5m
USD
|
Free Cash Flow Analysis
Bionano Genomics Inc
BNGO Profitability Score
Profitability Due Diligence
Bionano Genomics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Bionano Genomics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
BNGO Solvency Score
Solvency Due Diligence
Bionano Genomics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Bionano Genomics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNGO Price Targets Summary
Bionano Genomics Inc
Ownership
BNGO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BNGO Price
Bionano Genomics Inc
Average Annual Return | 75.22% |
Standard Deviation of Annual Returns | 270.37% |
Max Drawdown | -100% |
Market Capitalization | 45.9m USD |
Shares Outstanding | 61 230 700 |
Percentage of Shares Shorted | 9.67% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 299 full-time employees. The company went IPO on 2018-08-01. The firm offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. The company markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
Contact
IPO
Employees
Officers
The intrinsic value of one BNGO stock under the Base Case scenario is 4.58 USD.
Compared to the current market price of 0.75 USD, Bionano Genomics Inc is Undervalued by 84%.